-
May 28, 2024 | 
theoncologypharmacist.com | William King
At the 12th Annual Summit of the Association for Value-Based Cancer Care (AVBCC) in 2022, held October 19-21, in New York City, a panel of experts from Upstream Partners discussed the current state of value-based agreements (VBAs) in pharma and what lies ahead. The session was moderated by Burt Zweigenhaft, PhD, DLitt, Executive Director and Co-Founder of AVBCC.
-
Nov 20, 2023 | 
oncpracticemanagement.com | William King |Wayne Kuznar
Copyright © 2023 American Association for Cancer Research. Reprinted with permission.
-
Nov 17, 2023 | 
theoncologypharmacist.com | William King |Wayne Kuznar
Copyright © 2023 American Association for Cancer Research. Reprinted with permission.
-
Nov 8, 2023 | 
oncpracticemanagement.com | William King |Dawn Holcombe |Meg Barbor |Katie Lawrence
Madrid, Spain—A perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab demonstrated a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant placebo in patients with resectable non–small cell lung cancer.
-
Oct 5, 2023 | 
oncpracticemanagement.com | William King
Madrid, Spain—A perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) versus neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant placebo in patients with resectable non–small cell lung cancer (NSCLC).
-
Oct 5, 2023 | 
valuebasedcancer.com | William King
Madrid, Spain—A perioperative regimen of neoadjuvant nivolumab (Opdivo) plus chemotherapy followed by surgery and adjuvant nivolumab demonstrated a statistically significant and clinically meaningful improvement in event-free survival (EFS) versus neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant placebo in patients with resectable non–small cell lung cancer (NSCLC).
-
Sep 10, 2023 | 
theoncologypharmacist.com | Patricia Stewart |William King
"Preliminary Results of a Real-World Study of the Safety and Efficacy of Surufatinib in BTC" was originally published by CCA News.
Surufatinib, a small-molecule inhibitor targeting VEGFR1, VEGFR2, VEGFR3, FGFR1, and CSF-1R, has exhibited satisfactory clinical effectiveness and favorable safety and tolerability profiles when utilized as monotherapy in the treatment of patients with biliary tract cancer (BTC) in the second-line setting.
-
Sep 6, 2023 | 
oncpracticemanagement.com | William King
Copyright © 2023 Association for Accessible Medicines. Reprinted with permission.
-
Jun 21, 2023 | 
oncpracticemanagement.com | William King |Patricia A. Stewart |Nadia Jaber
“Loss of Y Chromosome in Men Makes Bladder Cancer More Aggressive” was originally published by the National Cancer Institute.
It was once thought that after guiding the development of male sex organs in a fetus, the Y chromosome did not do much else. But over the past few years, results from multiple studies have challenged that belief. The most recent evidence comes from a new study that suggests that the Y chromosome may actually protect men from aggressive bladder cancer.
-
May 3, 2023 | 
valuebasedcancer.com | William King
Madrid, Spain—Results from 3 phase 3 clinical trials demonstrated the superiority of targeted therapies over conventional chemotherapy in patients with oncogene-addicted non–small cell lung cancer (NSCLC), including ALK-positive advanced NSCLC; EGFR exon 20 insertion-mutation–positive, newly diagnosed or advanced NSCLC; and advanced RET fusion–positive NSCLC. These findings were reported during the European Society for Medical Oncology Congress 2023.
